Axsome Therapeutics Inc (AXSM)

[georgejjl]

Axsome Therapeutics now has a large sales and marketing team in place and working increase sales.

Sunosi® (solriamfetol):

Sunosi net product sales increased by 104% to $57.9 million in 2021 and increased 71% to $14.9 million in 4Q21 compared to the same periods in 2020.

In 4Q21, U.S. prescriptions increased by 4% compared to 3Q21.

Lori Englebert -- Senior Vice President, Commercial and Business Development

Hey, Ram. Thanks for the question. So, you know, I think it's very important for sales force especially during launch periods, and, in this case, you know, for Sunosi initially viewing this as somewhat of a relaunch coming over to us. You know, they need to stay focused on their priority targets.

And so, they will be deployed to high-prescribing, high-potential, high-value prescribers in the markets, respective markets. The AXS-05 sales force will primarily focus on those targets related to AXS-05, where we believe we will have the highest potential, and the same for the Sunosi. However, we do know that there is a very high overlap between prescribers. And, you know, as appropriate, we will leverage those synergies.

Good luck and GOD bless,